James E. Hosch

Arrogene, Inc. commercializes a cancer treatment technology and a proprietary molecular delivery platform. Its technology delivers peptide, protein and oligonucleotide therapeutics across the blood-brain barrier to cancer cells to prevent tumor growth or for imaging. The company was founded by Julia Ljubimova, Alexander Ljubimova, Keith Black and Eggehard Holler in 2006 and is headquartered in Los Angeles, CA.

Arrogene, Inc. commercializes a cancer treatment technology and a proprietary molecular delivery platform. Its technology delivers peptide, protein and oligonucleotide therapeutics across the blood-brain barrier to cancer cells to prevent tumor growth or for imaging. The company was founded by Julia Ljubimova, Alexander Ljubimova, Keith Black and Eggehard Holler in 2006 and is headquartered in Los Angeles, CA.

Arrogene, Inc. commercializes a cancer treatment technology and a proprietary molecular delivery platform. Its technology delivers peptide, protein and oligonucleotide therapeutics across the blood-brain barrier to cancer cells to prevent tumor growth or for imaging. The company was founded by Julia Ljubimova, Alexander Ljubimova, Keith Black and Eggehard Holler in 2006 and is headquartered in Los Angeles, CA.

Arrogene, Inc. commercializes a cancer treatment technology and a proprietary molecular delivery platform. Its technology delivers peptide, protein and oligonucleotide therapeutics across the blood-brain barrier to cancer cells to prevent tumor growth or for imaging. The company was founded by Julia Ljubimova, Alexander Ljubimova, Keith Black and Eggehard Holler in 2006 and is headquartered in Los Angeles, CA.